Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Low-dose IL-34 has no effect on osteoclastogenesis but promotes osteogenesis of hBMSCs partly via activation of the PI3K/AKT and ERK signaling pathways

Fig. 3

Inhibitor specific for ERK suppresses the osteogenic differentiation caused by low-dose IL-34. a, b Determination of suitable concentration of inhibitor. c–h Expression of COL1A1, RUNX2, and ERK signaling pathway proteins was determined by Western blotting analysis on day 3 of osteogenesis. i, k ALP staining and activity on day 3 of osteogenesis. j, l ARS and quantitation on day 12 of osteogenesis. m, o Expression of COL1A1 proteins was determined by immunofluorescence on day 3 of osteogenesis. n, p Expression of RUNX2 proteins was determined by immunofluorescence on day 3 of osteogenesis. All of the experiments were independently accomplished no less than three times. Data are means ± SD. *P < 0.05 vs. the control group on day 3, @P < 0.05 vs. the control group on day 12, #P < 0.05 vs. the IL-34 (0.001 ng/ml) group. Scale bars, ALP staining and ARS, 500 μm. Immunofluorescence, 25 μm

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512